Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Next Previous
Trial Profile

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin/ezetimibe (Primary) ; Fimasartan (Primary)
  • Indications Essential hypertension; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Boryung Pharmaceutical

Most Recent Events

  • 18 Oct 2024 Status changed from recruiting to completed.
  • 18 Jul 2024 Planned End Date changed from 1 Jun 2024 to 1 Sep 2024.
  • 18 Jul 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top